FR3029790B1 - Microbille d'hydrogel de chitosane - Google Patents

Microbille d'hydrogel de chitosane

Info

Publication number
FR3029790B1
FR3029790B1 FR1462367A FR1462367A FR3029790B1 FR 3029790 B1 FR3029790 B1 FR 3029790B1 FR 1462367 A FR1462367 A FR 1462367A FR 1462367 A FR1462367 A FR 1462367A FR 3029790 B1 FR3029790 B1 FR 3029790B1
Authority
FR
France
Prior art keywords
microbell
present
chitosan hydrogel
hydrogel
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1462367A
Other languages
English (en)
Other versions
FR3029790A1 (fr
Inventor
Renaud Lecler
Mickael Chausson
Pierre Douette
Guillem Rocasalbas
Sandrine Gautier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synolyne Pharma Be
Original Assignee
SYNOLYNE PHARMA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SYNOLYNE PHARMA filed Critical SYNOLYNE PHARMA
Priority to FR1462367A priority Critical patent/FR3029790B1/fr
Priority to EP15807844.4A priority patent/EP3229777A1/fr
Priority to PCT/EP2015/078770 priority patent/WO2016091778A1/fr
Priority to US15/535,313 priority patent/US20170326275A1/en
Publication of FR3029790A1 publication Critical patent/FR3029790A1/fr
Application granted granted Critical
Publication of FR3029790B1 publication Critical patent/FR3029790B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des microbilles d'hydrogel comprenant au moins de l'eau, du chitosane, au moins un composé polyphosphate, l'eau étant présente à une concentration d'au moins 85% en masse, d'hydrogel, lesdites microbilles présentant un diamètre moyen en nombre allant de 100 à 900 µm. La présente invention concerne également leur procédé de fabrication et leurs utilisations, en particulier dans des compositions pharmaceutiques ou des dispositifs médicaux, plus particulièrement pour le traitement d'une pathologie d'une articulation.
FR1462367A 2014-12-12 2014-12-12 Microbille d'hydrogel de chitosane Active FR3029790B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1462367A FR3029790B1 (fr) 2014-12-12 2014-12-12 Microbille d'hydrogel de chitosane
EP15807844.4A EP3229777A1 (fr) 2014-12-12 2015-12-07 Microbille d'hydrogel de chitosane
PCT/EP2015/078770 WO2016091778A1 (fr) 2014-12-12 2015-12-07 Microbille d'hydrogel de chitosane
US15/535,313 US20170326275A1 (en) 2014-12-12 2015-12-07 Chitosan Hydrogel Microbead

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1462367A FR3029790B1 (fr) 2014-12-12 2014-12-12 Microbille d'hydrogel de chitosane

Publications (2)

Publication Number Publication Date
FR3029790A1 FR3029790A1 (fr) 2016-06-17
FR3029790B1 true FR3029790B1 (fr) 2017-01-13

Family

ID=52589603

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1462367A Active FR3029790B1 (fr) 2014-12-12 2014-12-12 Microbille d'hydrogel de chitosane

Country Status (4)

Country Link
US (1) US20170326275A1 (fr)
EP (1) EP3229777A1 (fr)
FR (1) FR3029790B1 (fr)
WO (1) WO2016091778A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101666792B1 (ko) 2016-02-05 2016-10-17 주식회사 파마리서치프로덕트 핵산 및 키토산을 포함하는 온도감응성 하이드로겔 조성물
KR101916193B1 (ko) * 2016-08-25 2018-11-07 주식회사 파마리서치프로덕트 핵산 및 키토산을 포함하는 관절강 주사용 조성물
ES2671184B2 (es) * 2016-11-16 2019-02-04 Univ Miguel Hernandez De Elche Formulacion para liberacion modificada de sustancias activas o farmacos, uso y procedimiento de obtencion
CN109482110A (zh) * 2017-09-12 2019-03-19 中国科学院兰州化学物理研究所苏州研究院 一种壳聚糖水凝胶的制备方法与应用
CN108125920A (zh) * 2018-03-05 2018-06-08 清华大学 一种基于壳聚糖的滴丸剂基质微球材料及其制备方法
CN108904467A (zh) * 2018-08-01 2018-11-30 青岛农业大学 壳聚糖-植酸钠空心纳米胶囊的制备工艺及其应用
CN108904780B (zh) * 2018-08-24 2022-03-15 湖南金朋医疗器械有限公司 一种妇科凝胶剂及其制备方法
WO2020088577A1 (fr) * 2018-11-02 2020-05-07 Volt14 Solutions Liant pour électrode de batterie
KR102209051B1 (ko) * 2019-04-03 2021-01-28 국민대학교산학협력단 하이드로겔 비드를 포함하는 화학센서, 및 상기 화학센서를 포함하는 용기 및 전자 제품
WO2021091040A1 (fr) * 2019-11-04 2021-05-14 주식회사 엔도비전 Hydrogel utilisant du chitosane dérivé de champignon, ou des dérivés de celui-ci, et son procédé de production
CA3176918A1 (fr) * 2020-04-17 2021-10-21 Boston Scientific Scimed, Inc. Compositions hemostatiques et procedes associes
CN113125422B (zh) * 2021-04-16 2023-07-25 合肥工业大学 化学发光水凝胶微珠的制备方法、制得的水凝胶微珠及其应用
CN116041801A (zh) * 2023-02-14 2023-05-02 齐鲁工业大学(山东省科学院) 一种壳聚糖-植酸纳米颗粒的制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4122591C1 (en) * 1991-07-08 1993-02-18 Roland 8012 Ottobrunn De Bodmeier Producing microcapsules of water insoluble polymer and active agent - includes dissolving or dispersing active agent in aq. polymer contg. gellable assistants
EP2361640A1 (fr) * 2010-02-25 2011-08-31 Université de Liège Culture cellulaire dans les billes d'hydrogel à base d'alginate chitosan
CA2818894C (fr) * 2010-11-23 2019-02-12 Georgia Tech Research Corporation Administration de proteines a partir de microvecteurs de cellules souches
ES2770498T3 (es) * 2012-08-28 2020-07-01 Univ Geneve Hidrogeles híbridos
CN102920652B (zh) * 2012-11-26 2014-04-02 昆明医科大学 蜂胶壳聚糖牙周缓释温敏原位凝胶及制备方法
CN103071156A (zh) * 2012-12-12 2013-05-01 中国人民解放军第四军医大学 一种壳聚糖包裹负电荷金纳米粒及其制备方法和应用
BR102012033126B1 (pt) * 2012-12-21 2022-01-04 Universidade Estadual De Campinas - Unicamp Processo de obtenção de produtos a base de quitosana e enriquecidos com arrabidaea chica

Also Published As

Publication number Publication date
EP3229777A1 (fr) 2017-10-18
US20170326275A1 (en) 2017-11-16
WO2016091778A1 (fr) 2016-06-16
FR3029790A1 (fr) 2016-06-17

Similar Documents

Publication Publication Date Title
FR3029790B1 (fr) Microbille d'hydrogel de chitosane
MA38814A1 (fr) Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs
TN2019000126A1 (fr) Nouvelles compositions antivirales pour le traitement des infections liées aux coronavirus.
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA41013B1 (fr) Compositions comprenant des souches bactériennes
MA38406B1 (fr) Virus de la maladie de newcastle et leurs utilisations
MA46619B1 (fr) Anticorps anti-il-33 et leurs utilisations
MA41977B1 (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
MA43918A (fr) Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
MA41291A (fr) Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
MA38261A1 (fr) Composes comprenant un noyau polycyclique destines a etre utilises dans le traitement de l'hepatite c (vhc)
MA43982A (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA39359A1 (fr) Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés
MA41547B1 (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
FR3046610B1 (fr) Utilisation de 4,4-difluoro-4-bora-3a,4a-diaza-s-indacenes pour la securisation
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA39346A1 (fr) Hétérocycles substitués liés par fusion en tant que modulateurs gpr119 pour le traitement du diabète, de l'obésité, de la dyslipidémie et de troubles associés
MA35409B1 (fr) Utilisation de nanosystemes luminescents pour authentifier des documents securises
FR3033701B1 (fr) Nouvelles compositions antivirales pour le traitement de la grippe
FR3030257B1 (fr) Composition comprenant des particules de polymere et un epaississant mineral, procede la mettant en oeuvre
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MA39927B1 (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
MA39496A (fr) Inhibiteurs de mtor spécifiques dans le traitement de l'adrénoleucodystrophie liée à l'x
MA39407A1 (fr) Compositions de cyclodextrine et de dérivés de budésonide et procédés associés

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20160617

CD Change of name or company name

Owner name: SYNOLYNE PHARMA, BE

Effective date: 20160905

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10